MTOR and breast carcinoma: mTOR inhibitors, including rapamycin and the semi-synthetic derivative everolimus (EVE), are widely studied and applied in clinical trials for the treatment of cancer, showing specific beneficial effects in hormone receptor-positive (HR+) breast cancers [12].